IGALMI
Live / Applied — Second extension granted (statement of use) (as of 23 Mar 2026)
What this means for you
Not registered yet, but its 26 Jun 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98620766
- Mark type
- Stylized text
- Filed
- 26 Jun 2024
- Published for opposition
- 04 Feb 2025
- Attorney of record
- Brendan J. Hughes
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceuticals for the treatment of agitation, namely, an orally-dissolving formulation used for the treatment of agitation associated with alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, or other central nervous system disorders, namely, dementia and depression
Owner
- BioXcel Therapeutics, Inc., New Haven, CT, US
- BioXcel Therapeutics, Inc., New Haven, CT, US
Prosecution history
- 24 Mar 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 23 Mar 2026 — SOU EXTENSION 2 GRANTED
- 23 Mar 2026 — SOU EXTENSION 2 FILED
- 23 Mar 2026 — SOU TEAS EXTENSION RECEIVED
- 23 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 22 Sept 2025 — SOU EXTENSION 1 GRANTED
- 22 Sept 2025 — SOU EXTENSION 1 FILED
- 22 Sept 2025 — SOU TEAS EXTENSION RECEIVED
- 01 Apr 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 04 Feb 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 04 Feb 2025 — PUBLISHED FOR OPPOSITION
- 29 Jan 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 10 Jan 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 27 Dec 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 27 Dec 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE